Polaris Group
This article was originally published in Start Up
Executive Summary
Polaris Group's Phase II candidate is a microbial enzyme that degrades arginine, an amino acid crucial to tumor cell metabolism and growth. Depleting arginine from the blood can control tumor growth, but normal cells retain their ability to synthesize arginine so should not be harmed by the enzyme's effects.
You may also be interested in...
Start-Up Previews
This Month's Profile Groups: Upheaval and Opportunity Reshape The Oncology Market features profiles of Cyterix Pharmaceuticals, Polaris, Tocagen, Tragara Pharmaceuticals and VentiRx Pharmaceuticals. Patient-Centric Devices Promise Cost-Efficient Wound Care features profiles of Reapplix, Spiracur and Wound Solutions. Plus these Start-Ups Across Health Care: Cebix, Jan Medical, Life Recovery Systems, Respira and SeptRx.
Cyterix Pharmaceuticals Inc.
Cyterix Pharmaceuticals Inc. thinks it has found a way to safely increase the maximum tolerated dose of gemcitabine, a widely used cancer drug. The prodrugs that Cyterix is developing are meant to be activated by specific variants within a huge family of enzymes all classified as cytochrome P450 enzymes.
Tragara Pharmaceuticals Inc.
Tragara Pharmaceuticals Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy. This profile was adapted from an article that first appeared in the July issue of Pharmaceuticals Approval Monthly.